Safety and Efficacy Study of Prosaptide to Treat Neuropathic Pain in HIV-Positive Patients
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of Prosaptide Over 6 Weeks of Treatment for the Relief of Neuropathic Pain Associated With HIV-1|
- Differnece between the pain rating at Baseline vs. Week 6 (or last week)of treatment, based on the 13-point Gracely pain intensity scale as rated by subjects and captured in an electronic diary
- Difference between the Beline pain rating and each week of treatment.
- Number of subjects whoe were treatment successes at each week of the active treatment period.
|Study Start Date:||September 2003|
|Estimated Study Completion Date:||December 2004|
Sensory neruopathies are the most frequent neurological complicaton of HIV infection and its treatmet with antiretrovirals. To date, there are few effective treatments, and all are symptomatic treatments for pain. Management typically involves the intiation and adjustment of pain-modifying therapies, and the adjustment or discontinuation of potentially neurotoxic antiretrovirals, thereby limiting the choice of HAART regimens.
In precinical animal models,prosaptide has been shown to be efficacious in the treatment of neuropathic pain caused by a variety of different mechanisms.
Hypothesis: Prosaptide will improve neuropathic pain in HIV-associated sensory neuroathies,and will be safe and well tolerated in subjects.
Comparisons: 4, 8, or 16 mg prosaptide vs. placebo
Please refer to this study by its ClinicalTrials.gov identifier: NCT00286377
|Study Director:||Claudia Rehrig, MS||Savient Pharmaceuticals, Inc.|